Then, according to the genomic test eligibility criteria defined by the decree of the Ministry of Health of May 202123, i.e. early stage tumor, patients not at high or low risk of recurrence with hormone responsive and HER2 negative BC, 145 patients wase extracted. This evidence concerns the gene ERBB2 and breast cancer.